Cargando…

Gemcitabine enhances rituximab‐mediated complement‐dependent cytotoxicity to B cell lymphoma by CD20 upregulation

Although rituximab, a chimeric monoclonal antibody that specifically binds to CD20, has significantly improved the prognosis for diffuse large B cell lymphoma (DLBCL), one‐third of DLBCL patients demonstrate resistance to rituximab or relapse after rituximab treatment. Thus, a novel approach to ritu...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hayashi, Kazumi, Nagasaki, Eijiro, Kan, Shin, Ito, Masaki, Kamata, Yuko, Homma, Sadamu, Aiba, Keisuke
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2016
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4970836/ https://www.ncbi.nlm.nih.gov/pubmed/26920337 http://dx.doi.org/10.1111/cas.12918

Ejemplares similares

Up-regulation of HER2 by gemcitabine enhances the antitumor effect of combined gemcitabine and trastuzumab emtansine treatment on pancreatic ductal adenocarcinoma cells
por: Kan, Shin, et al.
Publicado: (2015)

Immunologic Monitoring of Cellular Responses by Dendritic/Tumor Cell Fusion Vaccines
por: Koido, Shigeo, et al.
Publicado: (2011)

Encryption of agonistic motifs for TLR4 into artificial antigens augmented the maturation of antigen-presenting cells
por: Ito, Masaki, et al.
Publicado: (2017)

Combinatorial Contextualization of Peptidic Epitopes for Enhanced Cellular Immunity
por: Ito, Masaki, et al.
Publicado: (2014)

Regulation of Tumor Immunity by Tumor/Dendritic Cell Fusions
por: Koido, Shigeo, et al.
Publicado: (2010)

In vitro generation of cytotoxic and regulatory T cells by fusions of human dendritic cells and hepatocellular carcinoma cells
por: Koido, Shigeo, et al.
Publicado: (2008)

Reduction of complement factor H binding to CLL cells improves the induction of rituximab-mediated complement-dependent cytotoxicity
por: Hörl, S, et al.
Publicado: (2013)

Reduction of complement factor H binding to CLL cells improves the induction of rituximab-mediated complement-dependent cytotoxicity
por: Hörl, S, et al.
Publicado: (2013)

Augmentation of Antitumor Immunity by Fusions of Ethanol-Treated Tumor Cells and Dendritic Cells Stimulated via Dual TLRs through TGF-β1 Blockade and IL-12p70 Production
por: Koido, Shigeo, et al.
Publicado: (2013)

Strategies to improve the immunogenicity of anticancer vaccines based on dendritic cell/malignant cell fusions
por: Koido, Shigeo, et al.
Publicado: (2013)

Overcoming bortezomib resistance in human B cells by anti-CD20/rituximab-mediated complement-dependent cytotoxicity and epoxyketone-based irreversible proteasome inhibitors
por: Verbrugge, Sue Ellen, et al.
Publicado: (2013)

Combined TLR2/4-Activated Dendritic/Tumor Cell Fusions Induce Augmented Cytotoxic T Lymphocytes
por: Koido, Shigeo, et al.
Publicado: (2013)

Bispecific mAb(2) Antibodies Targeting CD59 Enhance the Complement-Dependent Cytotoxicity Mediated by Rituximab
por: Stadlbauer, Katharina, et al.
Publicado: (2022)

Exploring complement-dependent cytotoxicity by rituximab isotypes in 2D and 3D-cultured B-cell lymphoma
por: Lara, Sandra, et al.
Publicado: (2022)

Upregulation of integrin‑linked kinase enhances tumor progression in gemcitabine‑resistant pancreatic cancer
por: Murase, Hiromichi, et al.
Publicado: (2023)

Antigen-Specific Polyclonal Cytotoxic T Lymphocytes Induced by Fusions of Dendritic Cells and Tumor Cells
por: Koido, Shigeo, et al.
Publicado: (2010)

Association of rituximab with graphene oxide confers direct cytotoxicity for CD20-positive lymphoma cells
por: Luo, Chengke, et al.
Publicado: (2016)

Effects of complement and serum IgG on rituximab-dependent natural killer cell-mediated cytotoxicity against Raji cells
por: Li, Yang, et al.
Publicado: (2019)

Antibody-CD20-interferon-alpha fusion protein has superior in vivo activity against human B cell lymphomas compared to Rituximab, and enhanced complement-dependent cytotoxicity in vitro
por: Yamada, Reiko, et al.
Publicado: (2013)

Fabrication and Cytotoxicity of Gemcitabine-Functionalized Magnetite Nanoparticles
por: Popescu, Roxana Cristina, et al.
Publicado: (2017)

Nanoencapsulated rituximab mediates superior cellular immunity against metastatic B-cell lymphoma in a complement competent humanized mouse model
por: Wen, Jing, et al.
Publicado: (2021)

In vitro synergistic cytotoxicity of gemcitabine and pemetrexed and pharmacogenetic evaluation of response to gemcitabine in bladder cancer patients
por: Mey, V, et al.
Publicado: (2006)

Improvement in Gemcitabine-Induced Thrombotic Microangiopathy with Rituximab in a Patient with Ovarian Cancer: Mechanistic Considerations
por: Murugapandian, Sangeetha, et al.
Publicado: (2015)

Complement and complement regulatory proteins are upregulated in lungs of COVID-19 patients
por: Ge, Xiaowen, et al.
Publicado: (2023)

T-cell lymphoma with abundant CD20 expression showing a good response to rituximab with gemcitabine, oxiplatin, and L-asparaginase (R-pGEMOX): A case report
por: Shao, Yajuan, et al.
Publicado: (2018)

Jo-1 Antibodies From Myositis Induce Complement-Dependent Cytotoxicity and TREM-1 Upregulation in Muscle Endothelial Cells
por: Honda, Masaya, et al.
Publicado: (2023)

Novel HDAC inhibitor Chidamide synergizes with Rituximab to inhibit diffuse large B-cell lymphoma tumour growth by upregulating CD20
por: Guan, Xu-Wen, et al.
Publicado: (2020)

Synergistic cytotoxicity of gemcitabine, clofarabine and edelfosine in lymphoma cell lines
por: Valdez, B C, et al.
Publicado: (2014)

Sorafenib improves rituximab and ofatumumab efficacy by decreasing the expression of complement regulatory proteins
por: Dwojak, M, et al.
Publicado: (2015)

Monitoring of the Complement System Status in Patients With B-Cell Malignancies Treated With Rituximab
por: Felberg, Anna, et al.
Publicado: (2020)

INTRARENAL COMPLEMENT FIXATION BY CYTOTOXIC ANTIBODIES
por: Sellin, D., et al.
Publicado: (1970)

Fusions between dendritic cells and whole tumor cells as anticancer vaccines
por: Koido, Shigeo, et al.
Publicado: (2013)

Wilms Tumor Gene (WT1) Peptide–based Cancer Vaccine Combined With Gemcitabine for Patients With Advanced Pancreatic Cancer
por: Nishida, Sumiyuki, et al.
Publicado: (2014)

Current Immunotherapeutic Approaches in Pancreatic Cancer
por: Koido, Shigeo, et al.
Publicado: (2011)

Intraductal Tubulopapillary Neoplasm Diagnosed Before Surgery: A Case Report
por: Senaha, Yoko, et al.
Publicado: (2023)

Cytotoxicity of gemcitabine-loaded thermosensitive liposomes in pancreatic cancer cell lines
por: Affram, Kevin, et al.
Publicado: (2015)

Macrophages increase the resistance of pancreatic adenocarcinoma cells to gemcitabine by upregulating cytidine deaminase
por: Amit, Moran, et al.
Publicado: (2013)

Vascular endothelial growth factor receptor 2-targeted ultrasound contrast agent selectively accumulates in pancreatic carcinoma in the allograft mouse model: A pilot study using time-intensity curve analysis of EUS imaging
por: Shimamoto, Nana, et al.
Publicado: (2019)

Overcoming rituximab drug-resistance by the genetically engineered anti-CD20-hIFN-α fusion protein: Direct cytotoxicity and synergy with chemotherapy
por: VEGA, GABRIEL G., et al.
Publicado: (2015)

Two is better than one: Complementing oncolytic virotherapy with gemcitabine to potentiate antitumor immune responses
por: Gujar, Shashi A, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_i3dvk76cqkumgj26jk8k38mpcj